Given Imaging to Host November 23rd Meeting and Webcast to Discuss New Features of PillCam(R) COLON2 and Review Results

YOQNEAM, ISRAEL, Nov 02 (MARKET WIRE) --
Given Imaging Ltd. (NASDAQ: GIVN), the global leader in capsule
endoscopy, today announced that it will host a meeting with members of
the financial community to discuss new features of the company's
second-generation PillCam(R) COLON and review results from the recently
completed Israeli feasibility study. The meeting will take place on
Monday, November 23rd at the Novotel London ExCel Hotel, Western Gateway,
Royal Victoria Dock, E16 1AA, London, UK. The meeting will begin at
2:00pm London Time, 9:00am New York Time, and 4pm Israel Time.

Speakers will include:

-- Homi Shamir, President and CEO of Given Imaging
-- Prof. Rami Eliakim, Rambam Medical Center and Prof. Sam Adler, Bikkur
Holim Hospital, principal investigators from the PillCam COLON2 feasibility
trial who will review results
-- Prof. Jacques Deviere, Erasme Hospital, Brussels will discuss the need
for alternatives to colonoscopy in Europe

If interested in attending the meeting in person, please call
+212-867-1768 or email dcarey@lazarpartners.com. To participate in the
teleconference, please dial one of the following numbers ten minutes
before the conference is scheduled to begin:

-- U.S. participants: 1-888-219-1217
-- U.K. participants: 08081017548
-- All other international callers please dial +913-312-1463 and include
appropriate codes for dialing the U.S.

This meeting will also be webcast live at www.givenimaging.com. A
replay of the call will be available for two weeks on the company's
website, or until December 7, 2009 by dialing 888-203-1112. Callers
outside of the U.S. should dial 719-457-0820. The replay participant code
is 8784603.

About PillCam COLON

PillCam COLON enables the physician to directly see the colon mucosa in
its natural state while not requiring sedation, intubation, air
insufflation, hospitalization or radiation. PillCam COLON is a smooth
plastic capsule which can be naturally ingested with a sip of water. It
utilizes advanced optical technology with tiny video cameras at each end,
which produces enhanced resolution images and includes automatic light
control and a wide field of view.

About Given Imaging Ltd.

Given Imaging has advanced gastrointestinal diagnosis by developing
innovative, patient-friendly tools based on its PillCam(R) Platform.
PillCam capsule endoscopy provides physicians with natural images of the
small intestine via PillCam(R) SB, the esophagus through PillCam(R) ESO,
and the colon with PillCam(R) COLON [PillCam COLON is not cleared for use
in the USA]. The PillCam capsules are miniature video cameras that
patients ingest. Given Imaging's other capsule products include Agile(TM)
patency capsule, to verify intestinal patency, and Bravo(R), the only
wireless, catheter-free, 48-hour pH test commercially available for pH
testing to assess gastroesophageal reflux disease (GERD). Given Imaging's
products use cutting-edge, wireless technology and advanced software to
enable gastroenterologists to evaluate and detect abnormalities of the
esophagus, small bowel and colon and more accurately treat patients. All
Given Imaging products allow patients to maintain normal activities.
Since 2001, more than one million PillCam(R) video capsules have helped
physicians evaluate patients for GI disorders. Given Imaging's
headquarters, manufacturing and R&D facilities are located in Yoqneam,
Israel, with operating subsidiaries in the United States, Germany,
France, Japan, Australia and Singapore. For more information, please
visit http://www.givenimaging.com.

This press release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but are not
limited to, projections about our business and our future revenues,
expenses and profitability. Forward-looking statements may be, but are not
necessarily, identified by the use of forward-looking terminology such as
"may," "anticipates," "estimates," "expects," "intends," "plans,"
"believes," and words and terms of similar substance. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors which may cause the actual events, results, performance,
circumstances or achievements of the Company to be materially different
from any future events, results, performance, circumstances or
achievements expressed or implied by such forward-looking statements.
Factors that could cause actual events, results, performance,
circumstances or achievements to differ from such forward-looking
statements include, but are not limited to, the following: (1) our
ability to develop and bring to market new products, (2) our ability to
receive regulatory clearance or approval to market our products or
changes in regulatory environment, (3) our success in implementing our
sales, marketing and manufacturing plans, (4) protection and validity of
patents and other intellectual property rights, (5) the impact of
currency exchange rates, (6) the effect of competition by other
companies, (7) the outcome of significant litigation, (8) our ability to
obtain reimbursement for our product from government and commercial
payors, (9) quarterly variations in operating results, (10) the
possibility of armed conflict or civil or military unrest in Israel, (11)
the impact of global economic conditions, and (12) other risks and
factors disclosed in our filings with the U.S. Securities and Exchange
Commission, including, but not limited to, risks and factors identified
under such headings as "Risk Factors," "Cautionary Language Regarding
Forward-Looking Statements" and "Operating Results and Financial Review
and Prospects" in the Company's Annual Report on Form 20-F for the year
ended December 31, 2008. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date of this
press release. Except for the Company's ongoing obligations to disclose
material information under the applicable securities laws, it undertakes
no obligation to release publicly any revisions to any forward-looking
statements, to report events or to report the occurrence of unanticipated
events.

For further information contact:

Fern Lazar/David Carey
Lazar Partners Ltd.
212-867-1768
Email Contact/
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-